Joby Aviation Is Spending $450 Million in Cash to Roughly Double Its Revenue

Joby Aviation agreed to buy Resonant Sciences for about $500M (about $450M cash + $50M stock), a deal that could roughly double Joby’s revenue on a matched 12-month basis. Resonant has >$100M trailing-twelve-month revenue (+~40% YoY) with positive adjusted EBITDA, and backlog more than doubled; Joby’s 2026 outlook is $115M–$125M, implying much of Resonant’s run-rate arrives before Joby’s air-taxi revenue scales. The acquisition won’t close until H1 2027 pending regulatory review, while Joby had about $2.3B cash/short-term investments (using $385M–$415M in 2H26 plus the $450M payment), reinforcing a longer-dated path to meaningful passenger revenue.

Analysis

The near-term market impact is less about the acquisition itself and more about what it signals: management is implicitly acknowledging that the standalone eVTOL path remains too slow to justify the current capital structure. The incremental revenue is useful, but because closing is pushed out to 2027, it does not relieve the 12-24 month financing story; the stock still trades on certification execution, not on this deal. The bigger second-order effect is dilution risk: the announced equity capacity creates a soft ceiling on multiple expansion because every rally can now be met with supply.

Competitive dynamics shift modestly in Joby’s favor if it can layer a defense business with positive EBITDA onto a pre-revenue mobility story, but that also changes the company’s identity. It becomes a hybrid software/defense/transportation asset, which may confuse investors and widen the valuation gap versus pure-play aerospace peers and versus eVTOL competitors like ACHR and EH that do not yet have a credible non-air-taxi revenue bridge. If the defense revenue is sticky, it could eventually lower the cost of capital; if not, it simply becomes a distraction that competes for management bandwidth and cash.

The contrarian miss is that the deal could be viewed as a de-risking step rather than a desperation move: a real, backlog-backed business with positive EBITDA is worth more than the market is giving it in a zero-revenue narrative. But the upside only matters if FAA milestones land on schedule and cash burn inflects before the new financing window opens. Falsifier: any slip in type certification, evidence the new stock-sale authorization is being tapped aggressively, or guidance that second-half burn remains unchanged into 2026.

Key Decisions for Investors

• Short JOBY on strength or via put spreads into certification headlines; use a 3-6 month horizon. Risk/reward favors downside if the market starts pricing 2027 dilution before any consolidated revenue benefit appears.
• Pair trade: long ITA or XAR vs short JOBY for 1-2 quarters. The thesis is that investors will rotate toward cash-generative aerospace/defense exposure while JOBY remains a financing story; cover if JOBY secures a materially better cash runway or accelerates FAA progress.
• If willing to express a binary catalyst, buy JOBY 6-12 month put spreads only on rallies above near-term resistance, with the stop set on a confirmed FAA milestone or evidence of faster-than-expected passenger revenue conversion.
• Watch ACHR and EH for relative weakness if the market interprets this as JOBY successfully broadening its moat; if they hold up better, it argues the market still views JOBY as a capital-destructive outlier rather than a category leader.